Pharmacometabolomics of Statin Response

2013/08/14 by Ronald M. Krauss, R M Krauss, H Zhu +3 · 17 citations
Biochemistry, Genetics and Molecular Biology · Medicine · #Metabolomics and Mass Spectrometry Studies #Cancer, Lipids, and Metabolism #Lipoproteins and Cardiovascular Health

paper · doi:10.1038/clpt.2013.164

Abstract

Statins reduce risk of cardiovascular disease (CVD) by decreasing plasma low-density lipoprotein (LDL) concentrations, as well as reducing inflammation and improving endothelial function. Despite their documented efficacy, there is considerable interindividual variation in effects of statins on CVD biomarkers. In the studies summarized here, we used complementary metabolomics platforms to define global effects of a statin (simvastatin) on metabolism and to identify markers indicative of mechanisms that contribute to variation in plasma LDL response to statin treatment.

Cited by

• Circadian regulation of lipid metabolism
• Metabolomics: A Tool Ahead for Understanding Molecular Mechanisms of Drugs and Diseases. [europepmc]
• Metabolomics enables precision medicine: "A White Paper, Community Perspective". [europepmc]
• Integration of pharmacometabolomics with pharmacokinetics and pharmacodynamics: towards personalized drug therapy. [europepmc]
• Endogenous and xenobiotic metabolic stability of primary human hepatocytes in long-term 3D spheroid cultures revealed by a combination of targeted and untargeted metabolomics. [europepmc]
• Pharmacometabolomics for predicting variable busulfan exposure in paediatric haematopoietic stem cell transplantation patients. [europepmc]
• Pharmacometabolomic signature links simvastatin therapy and insulin resistance. [europepmc]
• Intestinal Microbiota-Associated Metabolites: Crucial Factors in the Effectiveness of Herbal Medicines and Diet Therapies. [europepmc]
• Phosphatidylinositol-(4,5)-Bisphosphate Regulates Plasma Cholesterol Through LDL (Low-Density Lipoprotein) Receptor Lysosomal Degradation. [europepmc]
• Metabolomics and cardiovascular imaging: a combined approach for cardiovascular ageing. [europepmc]
• Serum Predose Metabolic Profiling for Prediction of Rosuvastatin Pharmacokinetic Parameters in Healthy Volunteers. [europepmc]
• Pharmacometabolomics for the Study of Lipid-Lowering Therapies: Opportunities and Challenges. [europepmc]
• Clinical Metabolomic Landscape of Cardiovascular Physiology and Disease. [europepmc]
• Effect of statin treatment on metabolites, lipids and prostanoids in patients with Statin Associated Muscle Symptoms (SAMS). [europepmc]
• Mini meta-analysis of anticholinesterase actions of atorvastatin, simvastatin and rosuvastatin, and in silico identification of their protein targets in Mus musculus . [europepmc]
• Multi-omics data integration from patients with carotid stenosis illuminates key molecular signatures of atherosclerotic instability. [europepmc]
• In-bedroom renewed air as anti-inflammatory adjuvant therapy in cancer survivors: protocol for the randomised, placebo-controlled BREATHS N-of-1 trial series. [europepmc]

Related

• PLEIOTROPIC EFFECTS OF STATINS
• Residual Cardiovascular Risk at Low LDL: Remnants, Lipoprotein(a), and Inflammation
• Human genetics suggests differing causal pathways from HMGCR inhibition to coronary artery disease and type 2 diabetes
• Impact of Statin Therapy on Plasma MMP-3, MMP-9, and TIMP-1 Concentrations: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials
• Factors underlying regression of coronary atheroma with potent statin therapy